speaker
🇸🇬 associate professor doctor doreen tan su-yiN
Pharm. D., BSc (Pharm)
NUHS Steering Committee for Pharmacogenomics
& PHARMFORCE Steering Committee
Doctor Doreen is an Associate Professor with NUS Department of Pharmacy and Pharmaceutical Sciences and Cardiology Specialist Pharmacist practicing at the National University Heart Center, Singapore. She is active with practice and precision medicine research. She wrote the grant for the implementation of individualisation of antiplatelets using CYP2C19 in clinical practice, fondly called “iRight4Me Antiplatelet Therapy”, which enrolled its 1007th patient in Feb 2024 before concluding the study.
She is an appointed member of the National University Health System’s Steering Committee for Pharmacogenomics. As part of her role the workgroup of education and training in the Steering Committee, she proactively wove cardiology-related Pharmacogenomics into the Undergraduate and Doctor of Pharmacy curriculum.
Doreen is co-investigator for Precision Health Research’s Clinical Implementation Pilot (PRECISE CIP: https://www.npm.sg/about-us/our-story/) and Study PI on “DTSY Statin Therapy” funded by the Ministry of Education – her most recent project on use of statin pharmacogenomics – it has commenced recruitment at the National University Polyclinics (NUP) in April 2024.
Doreen is also an enthusiast for translational research and digital health interventions. She is the pharmacist lead for the national pragmatic study AMI-HOPE (Acute Myocardial Infarction allied Health-Oriented Patient-centered digitally-Enabled care), a Ministry of Health-funded Health Services Development Programme (HSDP), a digital-based post-myocardial infarction care program delivered by specialty-trained collaborative prescriber Pharmacists.
Her other study, AdLip: Use of human-AI Symbiosis Personal Health Assistant to improve Adherence to Lipid-Lowering medications under CADENCE: https://www.cadence-cvd.sg/ will commence recruitment come June 2024. She has authored papers in the subject area of cardiovascular medicine and pharmacogenomics.
- Honorary Secretary, Council, Pharmaceutical Society of Singapore (PSS) (2024)
- Executive Committee, CADENCE, Consortium for Clinical Research & Innovation, Singapore (CRIS) (2023)
- Social Media Editor, European Heart Journal Cardiovascular Pharmacotherapy (2022)
- Cardiology Specialist Pharmacist, National University Heart Center, Singapore (NUHCS) (2022)
- Board of Director, International Society of Cardiovascular Pharmacotherapy (2021)
- Pharmacogenomics Steering Committee, National University Health System (2020)
- Associate Professor, Clinical & Pharmacy Practice, NUS Department of Pharmacy (2020)
- Co-Lead, Student-led Collaborative Innovative Pharmacy Inquiry (SCI-Phl) Project Year (2021)
- Content Expert, Cardio-Metabolic & Precision Medicine (2020)
- Faculty Advisor, Pre-Employment Clinical Training (PECT) (2020)
- PTPS, Policy, Research & Evaluation Dept (PRED)(2020)
- Assistant Director, Value Based Healthcare Office (2018)
- Head of Department, National Healthcare Group (KTPH Pharmacy)(2014)
awards & honours
- 2018 National Collaborative Prescribing Program Graduate, Ministry of Health & National University of Singapore
- 2012 Singapore Pharmacy Board Specialist Register for Cardiology Specialist Pharmacist
- Board Certified Pharmacotherapy Specialist from 2004, recertified in 2011
- Board Certified Pharmacotherapy Specialist Added Qualification in Cardiology from 2009
- Certified Geriatric Pharmacist from 2005
- Collaborative Institutional Training Initiative (CITI) certification on research ethics course
projects roles & research interest
As a Cardiology Specialist Pharmacist at the National University Hospital Heart Centre in Singapore (NUHCS), Dr. Doreen Tan provides a specialized pharmaceutical care. Additionally, she serves as the Faculty Advisor for the NUS Pharmacy Dept Pre-Employment Clinical Training (PECT) program.
She is also the Co-Lead of the Student-led Collaborative, Innovative Pharmacy Inquiry (SCI-PhI) Project at the NUS Pharmacy Department and the Associate Program Director for the R2 Cardiology Residency Pharmacy Residency Program under the Ministry of Health Singapore. Furthermore, she hold positions as the Board of Directors & Singapore Governor at the International Society of Cardiovascular Pharmacotherapy, and as the Workgroup Lead for Education (Pharmacy) at the NUHS Pre-Emptive Pharmacogenomics Steering Committee. She is also part of the Executive Committee and Co-Lead on Platform 3, and Lead of Use Case 3 (AdLip), CADENCE, Consortium for Clinical Research and Innovation, Singapore (CRIS).
Her research interests include Implementation Science and Pragmatic Trials in the context of Person-Centred Models of Care, Digital Health and AI in Cardiology Practice, Value-Driven Outcomes, Pharmacogenomics, and Cardiometabolic Disease Management, Pharmacotherapy, and Drug Interactions.
academic & professional distinctions
In the academic research, Dr Doreen is passionate in the pragmatic trials and implementation science, which also includes Pharmacogenomics, focusing on improving health and treatment outcomes for cardiometabolic disease management. She is also a researcher in studies linking the use of Pharmacogenomics in the management of cardiovascular diseases.
- 2023 Social Media Editor, EHJ Cardiovascular Pharmacotherapy
- 2023 Use Case 3 lead and Platform 3 co-lead, Consortium for Clinical Research and Innovation, Singapore (CRIS)’ CArdiovascular DiseasE National Collaborative Enterprise (CADENCE)
- 2023 Co-Investigator in the PRECISE grant for Pre-Emptive Pharmacogenomics
- 2023 Principal Investigator for a statin pharmacogenomics study – Designing Therapy to Suit You: Statin Pgx
- 2022 Editorial Board, European Cardiology Review
- 2022 Member, Steering Committee, PHARMFORCE (MOH Chief Pharmacist Office)
- 2020 Lead, PERSon-centred drUg-relAted problem reSolutION (PERSUASION) Pro-Tem Steering Committee
- 2019 Scientific Chairperson, International Society of Cardiovascular Pharmacotherapy 2021 Meeting
- 2019 Governor, Singapore, International Society of Cardiovascular Pharmacotherapy
- 2018 Writing Member, Agency of Care Effectiveness Appropriate Care Guidelines for the management of anticoagulation in Venous Thromboembolism
- 2017 Ministry of Health National Metrics Drug-related Problems and Productivity committee
- 2017 Member, Clinical Adoption Workgroup, Precision Medicine, MOH
- 2017 Member, Residency Policy and Oversight Committee
- 2017 Writing Member, Agency of Care Effectiveness Appropriate Care Guidelines for the management of anticoagulation in the Prevention of Stroke in Atrial Fibrillation
- 2016 Advisor, Pharmaceutical Society of Singapore’s Deprescribing Workgroup
- 2015 Chairman, Pharmaceutical Society of Singapore’s Pharmacy Week. Theme: Deprescribing for Inappropriate Polypharmacy
- 2015 Chairman, Pharmaceutical Society of Singapore’s Pharmacy Week. Theme: Deprescribing for Inappropriate Polypharmacy
- 2013 Appointed Part-time Professional Service to National Ministry of Health Guideline writing committee for Anticoagulation
- 2013 Scientific sub-committee of Singapore Pharmacy Congress
- 2012 Chairman, Pharmaceutical Society of Singapore’s Pharmacy Week. Theme: Just Ask Your Pharmacist
- Cheng Keat Tan, David Bin-Chia Wu, Seh Yi Joseph Tan, Syed Saqib Imran, Xue Ting Wee, Doreen Su-Yin Tan. Validating the Prognostic Utility of the ABCD-GENE Score in Asian Patients with Acute Coronary Syndrome Patients on Clopidogrel. European Cardiology Review 2023;18:e60.
- Wee J, Tan XR, Gunther SH, Ihsan M, Leow MKS, Tan DS, Eriksson JG, Lee JKW. Effects of medications on heat loss capacity in chronic disease patients: health implications amidst global warming. Pharmacol Rev. 2023 Jun 16:PHARMREV-AR-2022-000782. doi: 10.1124/pharmrev.122.000782. Epub ahead of print. PMID: 37328294.
- Tang SWY, Mai AS, Chew NWS, Tam WWS, Tan DS. The clinical impact of anti-hypertensive treatment drug-gene pairs in the asian population: a systematic review of publications in the past decade. J Hum Hypertens. 2023 Mar;37(3):170-180. doi: 10.1038/s41371-022-00765-y. Epub 2022 Oct 27. PMID: 36302845.
- Soh XQ, Tan DS, Chan ECY. Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore. Cardiovasc Drugs Ther. 2022 May 14. doi: 10.1007/s10557-022-07346-8. Epub ahead of print. PMID: 35567727.
- Tan, H. X., et al. (2022). “Applying the OMOP Common Data Model to Facilitate Benefit-Risk Assessments of Medicinal Products Using Real-World Data from Singapore and South Korea.” Healthc Inform Res 28(2): 112-122.
- Tan JWC, Chew DP, Tsui KL, Tan D, Duplyakov D, Hammoudeh A, Zhang B, Li Y, Xu K, Ong PJ, Firman D, Gamra H, Almahmeed W, Dalal J, Tam LW, Steg G, Nguyen QN, Ako J, Al Suwaidi J, Chan M, Sobhy M, Shehab A, Buddhari W, Wang Z, Fong AYY, Karadag B, Kim BK, Baber U, Chin CT, Han YL. 2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations. Eur Cardiol. 2021 Nov 8;16:e43. doi: 10.15420/ecr.2021.35. PMID: 34815751; PMCID: PMC8591619.
- Ng TM, Hing WC, Koh TY, Chang WT, Chang GSW, Heng JW, Abuaman IB, Sia BY, Saw YC, Chan D, Tan CH, Fan WS, Franky F, Tan PC, Tan CWY, Sng JHL, Yap CW, Gnanamani SUD, Tan DSY. Merits of a harmonised system to classify drug-related problems in Singapore. Ann Acad Med Singap. 2021 Jul;50(7):572-577. doi: 10.47102/annals-acadmedsg.202176. PMID: 34342338.
- Kim JH, Tan DS, Chan MYY. Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore. Pharmacogenomics J. 2021 Apr;21(2):243-250. doi: 10.1038/s41397-020-00204-6. Epub 2021 Jan 18. PMID: 33462345.
- Bhatt DL, Kaski JC, Delaney S, Alasnag M, Andreotti F, Angiolillo DJ, Ferro A, Gorog DA, Lorenzatti AJ, Mamas M, McNeil J, Nicolau JC, Steg PG, Tamargo J, Tan D, Valgimigli M. Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. Int J Cardiol. 2021 May 15:S0167-5273(21)00824-X. doi: 10.1016/j.ijcard.2021.05.012. Epub ahead of print. PMID: 34000356.
- Tan JW, Chew DP, Abdul Kader MAS, Ako J, Bahl VK, Chan M, Park KW, Chandra P, Hsieh IC, Huan DQ, Johar S, Juzar DA, Kim BK, Lee CW, Lee MK, Li YH, Almahmeed W, Sison EO, Tan D, Wang YC, Yeh SJ, Montalescot G. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region. Eur Cardiol. 2021 Mar 2;16:e02. doi: 10.15420/ecr.2020.40. PMID: 33708263; PMCID: PMC7941380.
- Narasimhalu K, Ang YK, Tan DSY, De Silva DA, Tan KB. Cost Effectiveness of Genotype-Guided Antiplatelet Therapy in Asian Ischemic Stroke Patients: Ticagrelor as an Alternative to Clopidogrel in Patients with CYP2C19 Loss of Function Mutations. Clin Drug Investig. 2020 Nov;40(11):1063-1070. doi: 10.1007/s40261-020-00970-y. PMID: 32959334.
- Chang GS, Tan DS. Using Pharmacogenetic Testing to Tailor Warfarin Therapy: The Singapore Experience and What the Future Holds. Eur Cardiol. 2020 Jun 29;15:e53. doi: 10.15420/ecr.2019.12. PMID: 32684983; PMCID: PMC7362335.
- Png WY, Wong XY, Kwan YH, Lin YY, Tan DS. Perspective on CYP2C19 genotyping test among patients with acute coronary syndrome – a qualitative study. Future Cardiol. 2020 Jun 11. doi: 10.2217/fca-2020-0036. Epub ahead of print. PMID: 32524842.
- Wee JW, Png WY, Wong XY, Kwan YH, Lin YY, Tan DS, Wee HL, Measuring preferences for CYP2C19 genotyping in patients with acute coronary syndrome – a discrete choice experiment. Future Cardiol, 2020.
- Patients’ and Caregivers’ Attitudes Towards Deprescribing in Singapore. J Gerontol A Biol Sci Med Sci, 2020. Kua, C.H., E. Reeves, Tan DSY et al on behalf of Pharmaceutical Society of Singapore’s Deprescribing Workgroup.
- Switching from Ticagrelor to Clopidogrel in Asian Patients with ST-Elevated Myocardial Infarction – A Time Dependent Analysis Study. Koh L, Kim JH, Tan DS, Leong WQ, Syed SI, Leow KL and Wee EW. Acta Cardiol Sin 2020;36:8E15.
- CYP2C19 phenotype in South‐East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events. Tan DS, Aw JWX, Winther M, Goh LL, Ong HY, Wee E, Liu J, Ho HK. J Clin Pharm Ther. 2019 Oct 31. doi: 10.1111/jcpt.13062. [Epub ahead of print]. https://doi.org/10.1111/jcpt.13062
- Sex Differences in 1-Year Rehospitalisation for Heart Failure and Myocardial Infarction after Primary Percutaneous Coronary Intervention. Zheng HL, Foo LL, Tan HC, et al. Am J Cardiology 2019; 123(12). DOI: 10.1016/j.amjcard.2019.03.021.
- Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Wang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RP. Eur Heart J. 2018 Dec 22. doi: 10.1093/eurheartj/ehy802. [Epub ahead of print]
- Expert Opinion. Using Pharmacogenetic Testing or Platelet Reactivity Testing to Tailor Antiplatelet Therapy: Are Asians different from Caucasians? Tan DSY. Eur Cardiology Review 2018.
- Comparison of rivaroxaban concentrations between Asians and Caucasians and their correlation with PT/INR. Ng HOT, Goh JJN, Aw JWX, Lin YY, Fong AYY, Tiong LL, Tan D. Journal of Thrombosis and Thrombolysis 2018.
- Drug Class, Renal Elimination, and Outcomes of Direct Oral Anticoagulants in Asian Patients: A Meta-Analysis. Wang KL, Chiu CC, Guigliano R, Tan D, Lin CY, Lai EY, Goto S, Chiang CE. Journal of Stroke and Cerebrovascular Diseases 2017; 27(4). DOI: 10.1016/j.strokecerebrovasdis.2017.10.027
- Incidence of thromboembolic and bleeding events in patients with newly diagnosed nonvalvular atrial fibrillation: An Asian multicenter retrospective cohort study in Singapore. Wee XT, Ho LM, Ho HK, Lee JYC, Yap CW, William H, Chan LCE, Tay HC, Goh CEM, Tan D. Clinical Cardiology 2017.
- Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. Lin L, Wu DBC, Abdul Aziz MI, Wong R, Sim D, Leong G, Yong QW, Tan D, Kwong N. Journal of Medical Economics 2017, published first online
- Once- or twice-daily non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A meta-analysis of randomized controlled trials. Wang KL, Chiu CC, Tan D, Lin CY, Lai EY, Goto S, Giugliano RP, Chiang CE. Jounral of the Formosan Medical Assoication 2017; 116:591-8
- Identifying Potentially Avoidable Readmissions: A Medication-Based 15-Day Readmission Risk Stratification Algorithm. Dorajoo SR, See V, Chan CT, Tan JZ, Tan DS, Abdul Razak SM, Ong TT, Koomanan N, Yap CW, Chan A . Pharmacotherapy. 2017 Mar;37(3):268-277
- Association between total daily doses with duration of hospitalization among readmitted patients in a multi ethnic asian population. Teo V, Toh MR, Kwan YH, Raaj S, Tan DSY, Tan JZY. Saudi Pharmaceutical Journal 2015
- Association between number of doses per day, number of medications and patient’s non-compliance, and frequency of readmissions in a multi-ethnic Asian population. Ming Ren Toh, Vivien Teo, Yu Heng Kwan, Sreemanee Raaj, Doreen Su-Yin Tan, Joyce Zhen Yin Tan. Preventive Medicine Reports 1 (2014) 43–47.
- Asian Study of CLOPidogrel Pharmacogenetics (ASCLOP), Int J Cardiol 2014 Feb 1;171(2):e21-3. doi: 10.1016/j.ijcard.2013.11.126. Epub 2013 Dec 12. PubMed PMID: 24377711. Tan DS, Yeo AH, Ho HK, Wee HL, Ong HY Tan DS, Yeo AH, Ho HK, Wee HL, Ong HY.